Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $37.40 USD
Change Today -1.18 / -3.06%
Volume 227.7K
CYNO On Other Exchanges
CYNO is not on other exchanges.
As of 5:20 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

cynosure inc-a (CYNO) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/26/15 - $40.52
52 Week Low
07/28/14 - $18.63
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CYNOSURE INC-A (CYNO)

cynosure inc-a (CYNO) Related Businessweek News

View More BusinessWeek News

cynosure inc-a (CYNO) Details

Cynosure, Inc. develops and markets aesthetic treatment systems for plastic surgeons, dermatologists, and other medical practitioners. It offers Elite product line for hair removal, and treatment of facial and leg veins and pigmentations; SmartLipo product line for LaserBodySculpting for the removal of unwanted fat; Cellulaze product line for the treatment of cellulite; Affirm/SmartSkin product line for anti-aging applications, including treatments for wrinkles, skin texture, skin discoloration, and skin tightening; and Cynergy product line for the treatment of vascular lesions. The company also provides Accolade, MedLite C6, and RevLite product lines for the removal of benign pigmented lesions, as well as multi-colored tattoos; PicoSure product line for the treatment of tattoos, benign pigmented lesions, acne scars, fine lines, and wrinkles; Icon aesthetic system for hair removal, wrinkle reduction, and scar and stretch mark treatment; and Vectus diode laser for high volume hair removal. In addition, it distributes PinPointe FootLaser for the treatment of onychomycosis. The company’s aesthetic treatment systems utilizes a range of energy sources, including Pulse dye, Alexandrite, CO2, Diode, Erbium, Er:YAG, and Nd:YAG lasers; and intense pulsed light devices. It sells its products through a direct sales force in North America, France, Morocco, Germany, Spain, the United Kingdom, Australia, China, Japan, and Korea, as well as through independent distributors in approximately 120 countries. The company was founded in 1991 and is headquartered in Westford, Massachusetts.

755 Employees
Last Reported Date: 03/13/15
Founded in 1991

cynosure inc-a (CYNO) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $2.1M
President, Chief Operating Officer, Chief Fin...
Total Annual Compensation: $1.4M
Executive Vice President of Worldwide Sales
Total Annual Compensation: $1.0M
Compensation as of Fiscal Year 2014.

cynosure inc-a (CYNO) Key Developments

Cynosure, Inc. Receives FDA 510 Clearance for Sculpsure

Cynosure, Inc. announced that it has received 510 clearance from the U.S. Food and Drug Administration to market SculpSure, the world's first hyperthermic laser treatment for non-invasive lipolysis of the flanks. The company plans to introduce SculpSure through its U.S. direct sales force late in the second half of 2015. Utilizing patented technology, SculpSure is a clinically proven and safe treatment designed to reduce fat non-invasively by disrupting subcutaneous fat cells. The versatile, hands-free device features a flexible applicator system to treat multiple anatomical areas of the body. SculpSure, which uses a 1060 nm laser, can treat an anatomical area in approximately 25 minutes. Patients are able to achieve desired results without downtime or surgery.

Cynosure, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Cynosure, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenues of USD 74,912,000 compared to USD 62,004,000 a year ago. Income from operations was USD 2,053,000 compared to USD 1,346,000 a year ago. Loss before income taxes was USD 12,000 compared to income before income taxes of USD 1,063,000 a year ago. Net loss was USD 8,000 compared to net income of USD 689,000 a year ago. Non-GAAP income from operations was USD 5,099,000 compared to USD 4,903,000 a year ago. Non-GAAP net income was USD 3,296,000 compared to USD 3,183,000 a year ago. Non-GAAP diluted net income per share was USD 0.15 compared to USD 0.19 a year ago.

Cynosure, Inc. to Report Q1, 2015 Results on May 05, 2015

Cynosure, Inc. announced that they will report Q1, 2015 results at 9:00 AM, US Eastern Standard Time on May 05, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYNO:US $37.40 USD -1.18

CYNO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dynatronics Corp $3.23 USD 0.00
Koninklijke Philips NV €23.33 EUR +0.51
Lutronic Corp 68,000 KRW +1,100
PhotoMedex Inc $1.30 USD -0.06
Zeltiq Aesthetics Inc $29.26 USD -0.21
View Industry Companies

Industry Analysis


Industry Average

Valuation CYNO Industry Range
Price/Earnings 27.7x
Price/Sales 2.7x
Price/Book 2.3x
Price/Cash Flow 25.4x
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYNOSURE INC-A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at